Zacks Investment Research upgraded shares of Catalent (NYSE:CTLT) from a hold rating to a buy rating in a research report report published on Tuesday, Zacks.com reports. They currently have $61.00 price objective on the stock.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
A number of other research analysts have also commented on the company. ValuEngine raised ZTE CORP/ADR from a hold rating to a buy rating in a report on Monday, April 15th. Jefferies Financial Group reaffirmed a buy rating on shares of Linde in a report on Friday, June 21st. UBS Group decreased their price objective on Spotify from $182.00 to $180.00 and set a buy rating on the stock in a report on Tuesday, April 16th. Finally, Morgan Stanley lowered GasLog Partners LP Unit from an overweight rating to an equal weight rating and decreased their price objective for the company from $23.00 to $18.00 in a report on Tuesday, April 16th. Nine analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and a consensus price target of $53.71.
Catalent (NYSE:CTLT) last posted its earnings results on Tuesday, May 7th. The company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.07. Catalent had a return on equity of 16.78% and a net margin of 6.01%. The business had revenue of $617.50 million for the quarter, compared to analyst estimates of $644.88 million. During the same period in the previous year, the firm earned $0.41 EPS. The firm’s revenue was down 1.7% compared to the same quarter last year. As a group, research analysts predict that Catalent will post 1.71 EPS for the current fiscal year.
In related news, Director Donald E. Morel, Jr. bought 10,000 shares of the business’s stock in a transaction dated Wednesday, May 15th. The stock was purchased at an average cost of $44.44 per share, for a total transaction of $444,400.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Peter L. Buzy bought 44,500 shares of the business’s stock in a transaction dated Wednesday, May 29th. The shares were bought at an average price of $45.13 per share, with a total value of $2,008,285.00. Following the completion of the transaction, the insider now owns 44,500 shares in the company, valued at approximately $2,008,285. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 56,500 shares of company stock valued at $2,542,845. Corporate insiders own 1.40% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC lifted its position in shares of Catalent by 17.6% during the 1st quarter. Janus Henderson Group PLC now owns 17,503,223 shares of the company’s stock worth $710,456,000 after buying an additional 2,620,352 shares during the last quarter. Norges Bank bought a new stake in shares of Catalent during the 4th quarter worth $47,177,000. BlackRock Inc. lifted its position in shares of Catalent by 7.9% during the 1st quarter. BlackRock Inc. now owns 13,918,974 shares of the company’s stock worth $564,971,000 after buying an additional 1,023,315 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its position in shares of Catalent by 39.0% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 2,369,230 shares of the company’s stock worth $73,872,000 after buying an additional 665,326 shares during the last quarter. Finally, Lazard Asset Management LLC lifted its position in shares of Catalent by 149.5% during the 1st quarter. Lazard Asset Management LLC now owns 741,200 shares of the company’s stock worth $30,085,000 after buying an additional 444,120 shares during the last quarter. Hedge funds and other institutional investors own 96.85% of the company’s stock.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Story: Should You Consider an Index Fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.